Company news

Transgene SA news in 2026

Transgene SA's news releases, calls and decks from 2026, newest first.

View company

Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026

October 5, 2026

Transgene to Participate in Investor Access

October 1, 2026

Transgene participera à l’Investor Access

September 30, 2026

Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field

September 24, 2026

Mise à disposition du Rapport Financier Semestriel au 30 juin 2026

September 23, 2026

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line

September 8, 2026

Transgene étend son partenariat stratégique avec ProBioGen par un nouvel accord de licence pour la lignée cellulaire AGE1.CR.pIX

September 7, 2026

Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

September 2, 2026

Transgene et NEC annoncent 100 % de survie sans récidive après 3 ans de suivi avec TG4050 et publient les résultats de la Phase 1 dans Nature Communications

September 1, 2026

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026

July 7, 2026

Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2026

July 6, 2026

Transgene présente des données précliniques de son vaccin innovant contre le mpox produit sur lignée cellulaire, TG-MVA

June 24, 2026

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

June 22, 2026

Transgene’s Combined General Meeting of May 22, 2026

May 22, 2026

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

May 4, 2026

Transgene Provides Business and Financial Update for Q1 2026

April 29, 2026

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

April 13, 2026

Availability of Transgene’s 2025 Universal Registration Document (URD)

April 9, 2026

Transgene to Participate in Upcoming Investor Meetings

April 7, 2026

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

April 2, 2026

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

March 26, 2026

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

March 24, 2026

Transgene Announces Financial Calendar for 2026

February 4, 2026

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero

January 23, 2026

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025

January 12, 2026

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

January 9, 2026

Calls in 2026

Decks in 2026